STOCK TITAN

[Form 4] Aardvark Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Aardvark Therapeutics (AARD) reported an insider option exercise by its Chief Operating Officer. On 10/15/2025, the officer exercised stock options (code M) to acquire 1,250 shares of common stock at an exercise price of $4.24 per share, held directly. Following the transaction, 40,052 derivative securities (stock options) remained beneficially owned.

The option carries an expiration date of 07/20/2034. Per the footnote, 1/48th vested on 07/27/2024 and continues vesting in equal monthly installments, subject to continuous service.

Aardvark Therapeutics (AARD) ha segnalato un esercizio di opzione interna da parte del suo Chief Operating Officer. Il 10/15/2025, l'ufficiale ha esercitato opzioni azionarie (codice M) per acquistare 1.250 azioni ordinarie a un prezzo di esercizio di $4,24 per azione, detenute direttamente. Dopo la transazione, 40.052 strumenti finanziari derivati (opzioni azionarie) sono rimasti beneficiariamente detenuti.

L'opzione ha una data di scadenza del 20/07/2034. Secondo la nota a piè di pagina, 1/48 è maturata il 27/07/2024 e continua a maturare in rate mensili uguali, soggetta a servizio continuo.

Aardvark Therapeutics (AARD) informó un ejercicio de opción interna por parte de su Director de Operaciones. El 10/15/2025, el directivo ejerció opciones sobre acciones (código M) para adquirir 1.250 acciones ordinarias a un precio de ejercicio de $4,24 por acción, mantenidas directamente. Tras la operación, quedaron poseídas de forma beneficiosa 40.052 valores derivados (opciones sobre acciones).

La opción tiene una fecha de vencimiento del 20/07/2034. Según la nota al pie, 1/48 se consolidó el 27/07/2024 y continúa consolidándose en cuotas mensuales iguales, sujeto a servicio continuo.

Aardvark Therapeutics (AARD)가 최고운영책임자(COO)의 내부자 옵션 행사 소식을 발표했습니다. 2025-10-15에, 해당 임원은 주식매수선택권(코드 M)을 행사하여 1,250주의 보통주를 주당 행사가 $4.24에 취득했으며, 직접 보유하고 있습니다. 거래 후, 40,052개의 파생증권(주식 옵션)이 여전히 유익하게 보유되었습니다.

이 옵션의 만료일은 2034-07-20입니다. 각주에 따르면, 1/482024-07-27에 소멸적립되었고, 계속해서 매월 같은 분할로 vesting되며, 지속적인 서비스에 따라 달라집니다.

Aardvark Therapeutics (AARD) a annoncé un exercice d’options internes par son directeur des opérations. Le 15/10/2025, le dirigeant a exercé des options d’achat (code M) pour acquérir 1 250 actions ordinaires à un prix d’exercice de 4,24 $ par action, détenues directement. Suite à la transaction, 40 052 titres dérivés (options d’achat) restaient détenus bénéficiairement.

L’option a une date d’expiration du 20/07/2034. Selon la note en bas, 1/48 est acquise le 27/07/2024 etcontinue de s’acquérir par versements mensuels égaux, sous réserve d’un service continu.

Aardvark Therapeutics (AARD) meldete eine Insider-Optionsausübung durch seinen Chief Operating Officer. Am 15.10.2025 übte der Offizier Aktienoptionen (Code M) aus, um 1.250 Aktien Stammaktien zu einem Ausübungspreis von $4,24 pro Aktie zu erwerben, die direkt gehalten wurden. Nach der Transaktion blieben 40.052 Derivate (Aktienoptionen) im wirtschaftlichen Besitz.

Die Option hat ein Verfallsdatum vom 20.07.2034. Laut Fußnote hat 1/48 am 27.07.2024 vested und vesting setzt sich in gleichen monatlichen Raten fort, vorbehaltlich kontinuierlicher Dienste.

Aardvark Therapeutics (AARD) أُعلن عن ممارسة خيار داخلي من قبل المدير التنفيذي للعمليات. في 15/10/2025، قام المسؤول بممارسة خيارات أسهم (الكود M) لاقتناء 1,250 سهماً من الأسهم العادية عند سعر ممارسة قدره $4.24 للسهم، محفوظه مباشرةً. بعد الصفقة، بقيت 40,052 ورقة أداة مشتقة (خيارات أسهم) مملوكة مستفادًا.

يحمل الخيار تاريخ انتهاء 20/07/2034. وفق الحاشية، 1/48 أصبح مُكتسباً في 27/07/2024 ويستمر في اكتساب الحقوق وفق أقساط شهرية متساوية، مع استمرار الخدمة.

Aardvark Therapeutics (AARD) 报告其首席运营官进行内部人期权行使。于 2025/10/15,该官员行使股票期权(代码 M)以在每股行使价 $4.24 购买 1,250 股普通股,直接持有。因此交易后,仍有 40,052 个衍生证券(股票期权)为受益所持有。

该期权的到期日为 2034/07/20。根据脚注,1/482024/07/27 已属权,并继续按月等额归属,前提是持续服务。

Positive
  • None.
Negative
  • None.

Aardvark Therapeutics (AARD) ha segnalato un esercizio di opzione interna da parte del suo Chief Operating Officer. Il 10/15/2025, l'ufficiale ha esercitato opzioni azionarie (codice M) per acquistare 1.250 azioni ordinarie a un prezzo di esercizio di $4,24 per azione, detenute direttamente. Dopo la transazione, 40.052 strumenti finanziari derivati (opzioni azionarie) sono rimasti beneficiariamente detenuti.

L'opzione ha una data di scadenza del 20/07/2034. Secondo la nota a piè di pagina, 1/48 è maturata il 27/07/2024 e continua a maturare in rate mensili uguali, soggetta a servizio continuo.

Aardvark Therapeutics (AARD) informó un ejercicio de opción interna por parte de su Director de Operaciones. El 10/15/2025, el directivo ejerció opciones sobre acciones (código M) para adquirir 1.250 acciones ordinarias a un precio de ejercicio de $4,24 por acción, mantenidas directamente. Tras la operación, quedaron poseídas de forma beneficiosa 40.052 valores derivados (opciones sobre acciones).

La opción tiene una fecha de vencimiento del 20/07/2034. Según la nota al pie, 1/48 se consolidó el 27/07/2024 y continúa consolidándose en cuotas mensuales iguales, sujeto a servicio continuo.

Aardvark Therapeutics (AARD)가 최고운영책임자(COO)의 내부자 옵션 행사 소식을 발표했습니다. 2025-10-15에, 해당 임원은 주식매수선택권(코드 M)을 행사하여 1,250주의 보통주를 주당 행사가 $4.24에 취득했으며, 직접 보유하고 있습니다. 거래 후, 40,052개의 파생증권(주식 옵션)이 여전히 유익하게 보유되었습니다.

이 옵션의 만료일은 2034-07-20입니다. 각주에 따르면, 1/482024-07-27에 소멸적립되었고, 계속해서 매월 같은 분할로 vesting되며, 지속적인 서비스에 따라 달라집니다.

Aardvark Therapeutics (AARD) a annoncé un exercice d’options internes par son directeur des opérations. Le 15/10/2025, le dirigeant a exercé des options d’achat (code M) pour acquérir 1 250 actions ordinaires à un prix d’exercice de 4,24 $ par action, détenues directement. Suite à la transaction, 40 052 titres dérivés (options d’achat) restaient détenus bénéficiairement.

L’option a une date d’expiration du 20/07/2034. Selon la note en bas, 1/48 est acquise le 27/07/2024 etcontinue de s’acquérir par versements mensuels égaux, sous réserve d’un service continu.

Aardvark Therapeutics (AARD) meldete eine Insider-Optionsausübung durch seinen Chief Operating Officer. Am 15.10.2025 übte der Offizier Aktienoptionen (Code M) aus, um 1.250 Aktien Stammaktien zu einem Ausübungspreis von $4,24 pro Aktie zu erwerben, die direkt gehalten wurden. Nach der Transaktion blieben 40.052 Derivate (Aktienoptionen) im wirtschaftlichen Besitz.

Die Option hat ein Verfallsdatum vom 20.07.2034. Laut Fußnote hat 1/48 am 27.07.2024 vested und vesting setzt sich in gleichen monatlichen Raten fort, vorbehaltlich kontinuierlicher Dienste.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Jones Bryan

(Last) (First) (Middle)
C/O AARDVARK THERAPEUTICS, INC.
4370 LA JOLLA VILLAGE DRIVE, SUITE 1050

(Street)
SAN DIEGO CA 92122

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Aardvark Therapeutics, Inc. [ AARD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Operating Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/15/2025 M 1,250 A $4.24 1,250 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock option (right to buy) $4.24 10/15/2025 M 1,250 (1) 07/20/2034 Common Stock 1,250 $0.00 40,052 D
Explanation of Responses:
1. 1/48th of the original number of shares subject to the option vested on July 27, 2024, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.
/s/ Nelson Sun, as Attorney-in-Fact 10/16/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Aardvark Therapeutics

NASDAQ:AARD

AARD Rankings

AARD Latest News

AARD Latest SEC Filings

AARD Stock Data

277.89M
18.54M
14.41%
50.61%
3.07%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO